I presented a case at Southern California Rheumatism society where we had challenges in managing skin condition and our patient responded well to JAK inhibitor for skin findings. I discussed this drug with a physician working on Brepocitinib trial who said its really a nice mechanism.
Finally, a difference in Placebo rates was noted in these graphs compared to previous JAK data.

From industy presentation tables to seeing them in NEJM format. Cant wait to do Journal club on this